RPG Life Sciences Q1 FY27: Revenue Grows 15.8% to ₹195.7 Cr, PAT Up 17.0% to ₹30.8 Cr
RPG Life Sciences reported Q1 FY27 results with revenue up 15.8% to ₹195.7 crore and PAT up 17.0% to ₹30.8 crore. Domestic Formulations grew 14.8%, APIs by 35.6%, and International Formulations by 7.7%. The company aims to scale core brands and expand its specialty and API businesses.
The announcement includes key financial results (revenue, PAT growth) and strategic business updates, which are material information for investors and significantly impact the company's valuation and stock performance.
The company reported strong year-on-year growth in revenue and PAT, along with positive segment-wise performance, indicating a favorable financial health and operational progress.
RPG Life Sciences Limited announced its unaudited financial results for the quarter ended June 30, 2026. The company reported a consolidated revenue from operations of ₹195.7 crore, marking a 15.8% increase compared to ₹168.9 crore in the same quarter last year. Profit After Tax (PAT), excluding exceptional items, grew by 17.0% to ₹30.8 crore, up from ₹26.3 crore in Q1 FY26. EBITDA also saw a significant rise of 17.9% to ₹48.0 crore.
Domestic Formulations (DF) remained the largest contributor, accounting for 68.3% of total sales, with a year-on-year growth of 14.8% to ₹132.5 crore. The API business contributed 13.7% to sales, reaching ₹26.6 crore, a growth of 35.6%, despite a fire incident impacting one manufacturing block. International Formulations (IF) contributed 18.0% to sales, growing by 7.7% to ₹35.0 crore.
The company also highlighted its strategic priorities, including scaling core brands like Naprosyn towards becoming a ₹100 crore+ brand, building a stronger specialty and chronic portfolio, strengthening the API business, and expanding its global presence. RPG Life Sciences received an investor presentation for its Q1 FY27 financial results on July 28, 2026.
What to do with a filing like this
RPG Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by RPG Life Sciences Limited. Read the original for the full detail.